Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment

An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment CASE REPORT An Uncommon Insertion Mutation in Exon 19 of EGFR  Showed Stable Disease after TKI Treatment Anthony W.H. Chan, FRCPA,* Joanna H.M. Tong, PhD,* Sing-Hung Lo, FRCR,† and Ka Fai To, FRCPA* n October 2010, a 55-year-old Chinese woman presented Iwith a T3N3M1a (stage IV) adenocarcinoma of left lung. She had left apical main tumor with carcinomatosis of both lungs, and metastatic lymphadenopathies of left hilar, right paratracheal, right supraclavicular, aortopulmonary, and sub- carinal lymph nodes. She presented with a Karnofsky perfor- mance score of 80% and an Eastern Cooperative Oncology FIGURE 1.  An insertion mutation by duplica- Group performance score of 1, and had never smoked. tion of 18 nucleotides at position 2214_2231  Molecular analysis was performed on a formalin-fixed (c.2232insTAAAATTCCCGTCGCTAT/ c.2214_2231dup)  and paraffin-embedded tissue derived by bronchoscopic in exon 19 leads to the insertion of 6 amino acids  transbronchial biopsy. Tumor cells were isolated from paraf- (p.K745_E746insIPVAIK). fin tissue by manual microdissection. Mutations in exons 18, 19, 20, and 21 of epidermal growth factor receptor (EGFR) gene were analyzed by polymerase chain reaction direct sequencing. An insertion mutation in exon 19 was identified: c.2232insTAAAATTCCCGTCGCTAT (c.2214_2231dup) p.K745_E746insIPVAIK (Fig. 1). Despite uncertain clinical response of this mutation at time of diagnosis, the patient preferred tyrosine kinase inhibi- tor (TKI) treatment over conventional chemotherapy, after detailed discussion with the oncologist. Erlotinib 150 mg once daily was initiated in December 2010. Patient’s symp- toms http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment

Journal of Thoracic Oncology , Volume 8 (12) – Dec 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/an-uncommon-insertion-mutation-in-exon-19-of-egfr-showed-stable-IJwoJH9NfK

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

CASE REPORT An Uncommon Insertion Mutation in Exon 19 of EGFR  Showed Stable Disease after TKI Treatment Anthony W.H. Chan, FRCPA,* Joanna H.M. Tong, PhD,* Sing-Hung Lo, FRCR,† and Ka Fai To, FRCPA* n October 2010, a 55-year-old Chinese woman presented Iwith a T3N3M1a (stage IV) adenocarcinoma of left lung. She had left apical main tumor with carcinomatosis of both lungs, and metastatic lymphadenopathies of left hilar, right paratracheal, right supraclavicular, aortopulmonary, and sub- carinal lymph nodes. She presented with a Karnofsky perfor- mance score of 80% and an Eastern Cooperative Oncology FIGURE 1.  An insertion mutation by duplica- Group performance score of 1, and had never smoked. tion of 18 nucleotides at position 2214_2231  Molecular analysis was performed on a formalin-fixed (c.2232insTAAAATTCCCGTCGCTAT/ c.2214_2231dup)  and paraffin-embedded tissue derived by bronchoscopic in exon 19 leads to the insertion of 6 amino acids  transbronchial biopsy. Tumor cells were isolated from paraf- (p.K745_E746insIPVAIK). fin tissue by manual microdissection. Mutations in exons 18, 19, 20, and 21 of epidermal growth factor receptor (EGFR) gene were analyzed by polymerase chain reaction direct sequencing. An insertion mutation in exon 19 was identified: c.2232insTAAAATTCCCGTCGCTAT (c.2214_2231dup) p.K745_E746insIPVAIK (Fig. 1). Despite uncertain clinical response of this mutation at time of diagnosis, the patient preferred tyrosine kinase inhibi- tor (TKI) treatment over conventional chemotherapy, after detailed discussion with the oncologist. Erlotinib 150 mg once daily was initiated in December 2010. Patient’s symp- toms

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Dec 1, 2013

There are no references for this article.